Autolus Therapeutics (AUTL) Misses Q1 EPS by 2c, Misses on Revenue; Offers FY26 Revenue Guidance

Autolus Therapeutics (NASDAQ: AUTL) reported Q1 EPS of ($0.27), $0.02 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $26.22 million versus the consensus estimate of $26.27 million.

GUIDANCE:

Autolus Therapeutics sees FY2026 revenue of $120-135 million, versus the consensus of $129.4 million.

For earnings history and earnings-related data on Autolus Therapeutics (AUTL) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance
• XORTX to voluntarily delist from TSX Venture Exchange